[Previous] Recover deleted data from hard disk even if its been delete...

 [Next] OECD Says Economic Damage Is Lasting, So Stimulus Should Conti...

Some related posts from Technorati and Google.

[Drugs.com - Clinical Trials] CytRx's Arimoclomol Demonstrates Statistically Significant ...: Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the predictive power of this or any other animal model of stroke recovery to humans, the outcome or results of any future pre-clinical or clinical testing of arimoclomol for stroke recovery, uncertainties related to the impact of the FDA's clinical hold on our clinical program for arimoclomol for the treatment of amyotrophic lateral sclerosis on the timing and ability to initiate further clinical development for stroke recovery, the risk that any requirements imposed on our planned clinical trial design for stroke recovery by the FDA as a result of the concerns expressed in their clinical hold of our ALS program might adversely affect our ability to demonstrate that arimoclomol is efficacious in treating stroke patients, risks related to CytRx's ability to enter into partnerships to advance the clinical development of arimoclomol, risks related to CytRx's need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, risks related to the future market value of CytRx's investment in RXi and the liquidity of that investment, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published.

[BioSpace.com Featured News and Stories] CytRx Corporation Says FDA Confirms Need for More Safety Data ...: Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the impact of the clinical hold on the timing and ability to resume and continue the Phase IIb clinical trial, as well as other risks or uncertainties described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published.

[Drugs.com - Clinical Trials] CytRx Announces Clinical Results from Its Rising Multiple Dose ...: Such statements involve risks and uncertainties thatcould cause actual events or results to differ materially from theevents or results described in the forward-looking statements,including risks or uncertainties regarding regulatory approvals forfuture clinical testing of arimoclomol, including CytRx's plannedPhase IIb clinical trial, and the scope of the clinical testingthat may be required by regulatory authorities for arimoclomol,uncertainties regarding the timing and amount of revenues, if any,that will be realized by CytRx from the commercialization ofarimoclomol, the significant time and expense that will be incurredin developing any of the potential commercial applications forarimoclomol and the potential need for additional capital to fundthe development of arimoclomol, as well as other risks oruncertainties described in CytRx's most recently filed SECdocuments, such as its most recent annual report on Form 10-K andany current reports on Form 8-K filed since the date of the lastForm 10-K. All forward-looking statements are based uponinformation available to CytRx on the date the statements are firstpublished.

[Latest Medical Technology from Bio-Medicine.Org] PRA International: Participating Sponsor for Exploratory Clinical ...: With harmonized clinical and laboratory facilities, 228 beds in Europe and the US and an innovative Early Development model that brings the center to the patients in Central/Eastern Europe, PRA's EDS group provides comprehensive services for Phase I and Phase IIa studies. PRA's integrated data support, in-house pharmacy and expedited regulatory approval timelines in The Netherlands enable PRA to reduce timelines for sponsors.

Reflected tags on Technorati: Blog, Data Recovery Los Angeles, Data Recovery Reports